Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
Corresponding Author
Jian Gao Fan
Department of Gastroenterology, Shanghai Key Laboratory of Children's Digestion and Nutrition, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Lai Wei
Hepatology Institute, Peking University People’s Hospital, Beijing, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Hui Zhuang
Peking University Health Science Center, Beijing, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorOn behalf of the National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association
Search for more papers by this authorCorresponding Author
Jian Gao Fan
Department of Gastroenterology, Shanghai Key Laboratory of Children's Digestion and Nutrition, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Lai Wei
Hepatology Institute, Peking University People’s Hospital, Beijing, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorCorresponding Author
Hui Zhuang
Peking University Health Science Center, Beijing, China
Correspondence
Jian Gao Fan, Department of Gastroenterology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Children's Digestion and Nutrition, 1665 Kongjiang Road, Shanghai 200092, China. Email: [email protected]
Wei Lai, Hepatology Institute, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Email: [email protected]
Hui Zhuang, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Email: [email protected]
Search for more papers by this authorOn behalf of the National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association
Search for more papers by this author
CONFLICT OF INTEREST
None.
REFERENCE
- 1Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22): 2263-2272.
- 2Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017; 377(21): 2063-2072.
- 3Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(12): 2099-2108.
- 4Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4): 862-873.
- 5Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014; 59(10): 2571-2579.
- 6Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis. 2011; 12(1): 38-44.
- 7LaBrecque DR, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014; 48(6): 467-473.
- 8Wong VW, Chan WK, Chitturi S, et al. The Asia–Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017—part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018; 33(1): 70-85.
- 9Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357.
- 10 European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388-1402.
- 11Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924-926.
- 12Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalconolic fatty liver disease. Hepatology. 2005; 41(6): 1313-1321.
- 13Brunt EM. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. Hepatol Commun. 2017; 1(5): 370-378.
- 14Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73-84.
- 15Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol. 2015; 21(18): 5695-5706.
- 16Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015; 62(1): 182-189.
- 17Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013; 108(8): 1299-1304.
- 18Xun YH, Fan JG, Zang GQ, et al. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. J Dig Dis. 2012; 13(11): 588-595.
- 19Shen F, Zheng RD, Shi JP, et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int. 2015; 35(11): 2392-2400.
- 20Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016; 65(8): 1359-1368.
- 21Zhang RN, Zheng RD, Mi YQ, et al. APOC3 rs2070666 is associated with the severity of hepatic steatosis independently of PNPLA3 rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases. Dig Dis Sci. 2016; 61(8): 2284-2293.
- 22Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study. J Hepatol. 2012; 57(5): 1153-1154.
- 23Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One. 2010; 5(7):e11578.
- 24Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 2013; 13: 3.
- 25Xu CF, Wan XY, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 2015; 62(6): 1412-1419.
- 26Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017; 65(5): 1557-1565.
- 27Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017; 65(1): 54-64.
- 28Wang Y, Wang B, Shen F, Fan J, Cao H. Body mass index and risk of primary liver cancer: a meta-analysis of prospective studies. Oncologist. 2012; 17(11): 1461-1468.
- 29Wong VW, Wong GL, Yeung JC, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology. 2016; 63(3): 754-763.
- 30Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31(5): 936-944.
- 31Chen GY, Cao HX, Li F, et al. New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel cohort. J Diabetes Investig. 2016; 7(2): 206-211.
- 32Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016; 6:33386.
- 33Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016; 65(3): 589-600.
- 34Wu R, Hou F, Wang X, et al. Nonalcoholic fatty liver disease and coronary artery calcification in a Northern Chinese population: a cross sectional study. Sci Rep. 2017; 7(1): 9933.
- 35Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014; 11(7):e1001680.
- 36Zeng J, Sun C, Sun WL, et al. Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults at a health check-up. J Dig Dis. 2017; 18(4): 229-236.
- 37Ding W, Fan J, Qin J. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. Int J Clin Exp Med. 2015; 8(1): 322-333.
- 38Chitturi S, Wong VW, Chan WK, et al. The Asia–Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017—part 2: management and special groups. J Gastroenterol Hepatol. 2018; 33(1): 86-98.
- 39 European Association for Study of Liver, Asociación Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63(1): 237-264.
- 40Xu L, Lu W, Li P, Shen F, Mi YQ, Fan JG. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in patients with chronic hepatitis B. Dig Liver Dis. 2017; 49(8): 910-917.
- 41Shen F, Zheng RD, Mi YQ, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol. 2014; 20(16): 4702-4711.
- 42Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66(5): 1022-1030.
- 43Shen F, Zheng RD, Mi YQ, et al. Value of a two-step approach with cytokeratin-18 and controlled attenuation parameter in noninvasive differential diagnosis of nonalcoholic steatohepatitis. Chin J Hepatol. 2016; 24(6): 429-434. (in Chinese).
- 44Bedossa P, Burt AD, Gouw ASH, et al.; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014; 60(2): 565-575.
- 45Petta S, Wong VW, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology. 2017; 65(4): 1145-1155.
- 46Zeng J, Sun WL, Chen GY, et al. Efficiency of FibroScan and FibroTouch in liver stiffness measurement and fat quantification: a comparative analysis. Chin J Hepatol. 2016; 24(9): 652-658. (in Chinese).
- 47Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017; 152(6): 1544-1577.
- 48Yu CH, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol. 2012; 56(1): 241-247.
- 49Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013; 59(4): 859-871.
- 50Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017; 67(4): 829-846.
- 51Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013; 59(3): 536-542.
- 52Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013; 28(Suppl): 81-87.
- 53Zhang HJ, He J, Pan LL, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med. 2016; 176(8): 1074-1082.
- 54Zhang HJ, Pan LL, Ma ZM, et al. Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: a 1-year follow-up study. Diabetes Obes Metab. 2017; 19(2): 284-289.
- 55Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015; 62(1): 190-197.
- 56Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376(9756): 1916-1922.
- 57Bril F, Portillo Sanchez P, Lomonaco R, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. J Clin Endocrinol Metab. 2017; 102(8): 2950-2961.
- 58Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387(10019): 679-690.
- 59Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016; 165(5): 305-315.
- 60Brito JP, Montori VM, Davis AM. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. JAMA. 2017; 317(6): 635-636.
- 61Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology. 2017; 65(4): 1156-1164.
- 62 Chinese Society of Infectious Diseases, Chinese Medical Association, Expert Committee for Prevention and Management of Liver Inflammation. Consensus statement by the expert committee for prevention and management of liver inflammation in China. Chin J Hepatol. 2014; 22(2): 94-103. (in Chinese).
- 63Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18): 1675-1685.
- 64Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385(9972): 956-965.
- 65Han Y, Shi JP, Ma AL, Xu Y, Ding XD, Fan JG. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 2014; 34(1): 1-7.
- 66Chan WK, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017; 15(12): 1940-1949.e8.
- 67Newsome PN, Allison ME, Andrews PA, et al.; British transplant society. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut. 2012; 61(4): 484-500.
- 68Pais R, Barritt AS, Calmus Y, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol. 2016; 65(6): 1245-1257.
- 69Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017; 65(6): 2090-2099.
Citing Literature
